Northeast Pharmaceutical Group Co., Ltd. (referred to as "Northeast Pharmaceutical") is a listed company under Liaoning Fangda Group Industrial Co., Ltd. (referred to as "Fangda Group"). The company was formerly known as Northeast Pharmaceutical General Factory, founded in 1946. Listed on the Shenzhen Stock Exchange in 1996, stock code: 000597. Northeast Pharmaceutical once assisted in the construction of 52 pharmaceutical enterprises in 19 provinces and cities across the country, and sent more than 1300 cadres abroad, known as the cradle of China's national pharmaceutical industry. Northeast Pharmaceutical is an important pharmaceutical production and export base in China, one of the largest monomer formulation production bases in China, a production base for Chinese hemp extract drugs and anti HIV drugs, a national demonstration factory for intelligent manufacturing of bulk raw materials and pharmaceutical intermediates, and a national enterprise technology center and innovative drug incubation base.

Northeast Pharmaceutical has major business segments including chemical raw materials, chemical preparations, pharmaceutical commerce, pharmaceutical engineering, and biomedicine, covering the entire industry chain of pharmaceutical research and development, manufacturing, and distribution. It has a workforce of over 6000 people and total assets of 15.606 billion yuan. We have two major production bases for active pharmaceutical ingredients and formulations. The formulation production base covers an area of 180000 square meters and has more than 30 production lines, with an annual production capacity of 13.3 billion tablets (tablets, pills, granules, pills, bottles). The raw material production base covers an area of 910000 square meters with an annual production capacity of over 30000 tons. It is a national demonstration factory for intelligent manufacturing of bulk raw materials and pharmaceutical intermediates. Its main products include vitamin C and its series, L-carnitine series, phosphomycin series, piracetam, carboprost methyl ester, amantadine hydrochloride, sucralfate, berberine, chloramphenicol, etc., and it extends downstream to the northeast pharmaceutical formulation industry chain, forming a comprehensive competitive advantage that is difficult to replicate.

Northeast Pharmaceutical mainly produces ten series of high-quality products, including vitamin series drugs, anti infection system drugs, obstetrics and gynecology system drugs, digestive system drugs, urinary system drugs, antiviral series drugs, cardiovascular and cerebrovascular series drugs, analgesic and cough relief series drugs, biological diagnosis series, and big health field series drugs. It has more than 400 chemical raw materials, pharmaceutical intermediates, and formulation products, and owns two well-known Chinese trademarks, "Northeast" and "Fumeixin", as well as multiple famous trademarks. Its leading products are exported to more than 100 countries and regions.

Northeast Pharmaceutical has a national level enterprise technology center and innovative drug incubation base, and continuously deepens strategic cooperation with top research institutions such as the Chinese Association for Science and Technology Life Science Society and the Chinese Academy of Sciences. While continuously optimizing existing products, the company is implementing a cross generational innovation strategy, focusing on the field of biological innovative drugs and laying out the development and transformation of solid tumor cell therapy products. In 2024, the company acquired 70% equity of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. Through the established ADC drug and CAR-T research and development platforms, as well as TCR-T and TCR protein drug research and development platforms, it quickly entered the forefront of innovative biological drugs and formed a dual innovation driven pattern of innovative drugs leading and generic drugs following. Northeast Pharmaceutical has a strong pharmaceutical research and development team, with over a hundred full-time senior researchers in the technical center, and has produced the first academician of the Chinese Academy of Engineering, Jing Qingxian, among national pharmaceutical enterprises. Zidovudine (trade name: "Kedu"), a drug substance, tablet and capsule produced by the company itself, is the first anti HIV drug in China, ending the history of China's dependence on imports of anti AIDS drugs. The development of AIDS detection kit covers nine HIV-1 genotypes, filling the domestic gap. At the same time, in the field of anesthesia and psychotropic drugs, the company is a designated manufacturer of anesthetic drugs by the state.

Northeast Pharmaceutical has a sound quality management system, and its product quality meets the latest quality standards such as EP, USP, JP, BP, ChP, etc. Multiple products have successively passed EDQM FDA、 International high-end certifications such as Japan's Ministry of Health, Labour and Welfare, BRC, HALAL, KOSHER, etc. The leading products have passed registration and quality audits in multiple countries and regions including the United States, Europe, Japan, Brazil, Russia, Poland, etc.

Since 2018, Fangda Group has become the controlling shareholder of Northeast Pharmaceutical's listed company through mixed ownership reform, introducing a new system and mechanism for the enterprise, comprehensively innovating management, business, and efficiency models, and opening a new chapter in the fully market-oriented development of Northeast Pharmaceutical. Looking towards the future, Northeast Pharmaceutical will introduce talents and technology through globalization, and create an internationally leading comprehensive pharmaceutical and health industry group led by technological innovation.